At the 2025 European Lung Cancer Conference (ELCC), Professor Antonio Passaro from the European Institute of Oncology (IEO), Italy, led a deep discussion during the controversy session on the topic, "Optimizing the first-line treatment of EGFR-mutant NSCLC: Has the time for TKI combinations arrived?"Oncology Frontier: You discussed the topic, “Should TKI combination therapy be considered as the standard first-line treatment for EGFR-mutant NSCLC?” at the 2025 ELCC. Could you share your perspective on this?
Dr. Passaro: During this ELCC, the final overall survival data from the MARIPOSA trial will be presented. The trial combination of amivantamab/lazertinib versus osimertinib alone was the first randomized phase III trial versus osimertinib to confirm the significant improvement in overall survival. The data that will be discussed this afternoon by Professor Yang are very impressive and confirm the need to try to prioritize combination therapy in the first-line setting, not only in patients with high-risk features, but for other patients as well. The emergence of combination therapy is opening a new era for patients with EGFR alterations.
Oncology Frontier: Among the lung cancer studies presented at ELCC 2025, which results do you believe will have the greatest impact on clinical practice?
Dr. Passaro: Of course, the MARIPOSA study. The MARIPOSA trial will open up a new era for patients with non-small cell lung cancer, particularly with EGFR mutations. The MARIPOSA data combined with other results confirm the significant reduction in toxicity which will be key for success in this particular setting.
Oncology Frontier: At ELCC 2025, you presented a poster titled, “Evanmab Monotherapy for Treated EGFR Exon 20 Insertion Mutant NSCLC: Efficacy and Safety Real-World Data from the Italian Biomarker ATLAS Database” (Abstract 70P). What were the key findings of this study?
Dr. Passaro: Here, we have reported the data from our post-hoc analysis using amivantamab in patients with exon 20 mutations. This is the first real-world data for amivantamab in patients with exon 20 after chemotherapy that confirm the data from the CHRYSALIS trial in a real-world setting. This data confirmed the use of amivantamab in this setting with a safety profile able to be managed in a clinical setting.
Reference
1.Amivantamab Plus Lazertinib vs Osimertinib in First-line (1L) EGFR-mutant (EGFRm) Advanced NSCLC: Final Overall Survival (OS) from the Phase 3 MARIPOSA Study. 2025 ELCC, abstract 4O.
2.Passaro A, et al. Amivantamab monotherapy in patients with pre-treated NSCLC with EGFR Exon 20 Insertion Mutations: Real-World Data on efficacy and safety from the Italian biomarker ATLAS database. 2025 ELCC, abstract 70P.
